Home Itens selecionados Provedores de dados OAI Créditos Sobre Ajuda

			Busca avançada
	Provedor de dados 55 (5) Autor Amarante,Jorge B. (1) Barber,Katie E. (1) Barone,Antonio A. (1) Bell,Allison M. (1) Biancalana,Maria L. (1) Feinstein,Max M. (1) Gortz,Lucas W. (1) Hernández-Gómez,Cristhian (1) Kiffer,Carlos R. V. (1) Kiffer,Carlos R.V. (1) King,S. Travis (1) Kuti,Joseph L. (1) Machado,Flavia R (1) Mendes,Caio M.F. (1) Nicolau,David P. (1) Oplustil,Carmen P. (1) Ordóñez,Karen (1) Pallares,Christian (1) Parham,Jason J. (1) Reyes,Sergio (1) Mais... Palavra-chave Meropenem (5) Antibiotic resistance (1) Antimicrobial stewardship program (1) Carbapenem (1) Costs (1) Critical care (1) Generic drugs (1) Gram negative bacteria (1) Imipenem (1) Intensive care unit (1) Mortality (1) Nosocomial pneumonia (1) Pharmaceutical (1) Pharmacodynamics (1) Piperacillin (1) Pseudomonas aeruginosa (1) Resistance (1) Risk factor (1) Mais... Tipo do documento Info:eu-repo/semantics/article (4) Info:eu-repo/semantics/other (1) Ano 2019 (1) 2016 (1) 2012 (1) 2007 (1) 2001 (1) País Brazil (5) Idioma Inglês (5)		Ordenar por:  Relevância Autor Título Ano Registros recuperados: 5 Primeira ... 1 ... Última Impact of piperacillin-tazobactam shortage on meropenem use: implications for antimicrobial stewardship programs 55 Barber,Katie E.; Bell,Allison M.; King,S. Travis; Parham,Jason J.; Stover,Kayla R.. ABSTRACT Drug shortages pose a clear detriment to antimicrobial stewardship (AS) efforts. Our objective was to evaluate the effect of a piperacillin-tazobactam shortage on meropenem use, related costs, and associated changes in AS activity. A quasi-experimental quality improvement review compared adult patients receiving meropenem ≥72 h three months pre-shortage and three months during the shortage. 320 patients were included (pre-shortage: 103; shortage: 217). Baseline characteristics were similar, but the length of stay was slightly longer in pre-shortage [19 (11-32) days] versus shortage [16 (11-32) days] (p = 0.094). In pre-shortage and shortage, median days of therapy and estimated meropenem cost were 7 (5-11) and 7 (5-10) and $309.93... Tipo: Info:eu-repo/semantics/other Palavras-chave: Piperacillin; Meropenem; Pharmaceutical; Antimicrobial stewardship program. Ano: 2016 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702016000600631 Clinical and economic impact of generic versus brand name meropenem use in an intensive care unit in Colombia 55 Ordóñez,Karen; Feinstein,Max M.; Reyes,Sergio; Hernández-Gómez,Cristhian; Pallares,Christian; Villegas,María V.. Abstract Background: Recent studies suggest that sustained use of generic antibiotics may be associated with clinical failure and emergence of antibacterial resistance. The present study was designed to determine the clinical outcome between the use of generic meropenem (GM) and brand-name meropenem (BNM). Additionally, this study evaluated the economic impact of GM and BNM to determine if the former represents a cost-effective alternative to the latter. Methods: Patients treated between January 2011 and May 2014 received GM while patients treated between June 2014 and March 2017 received BNM. Mortality was compared between groups. Total infection cost was defined by the cost of antimicrobial consumption, length of stay, and laboratory and imaging exams... Tipo: Info:eu-repo/semantics/article Palavras-chave: Generic drugs; Meropenem; Mortality; Costs; Critical care; Gram negative bacteria. Ano: 2019 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702019000400237 A pharmacodynamic strategy to optimize empirical antibiotic therapy for gram-negative bacteria in a Brazilian Intensive Care Unit 55 Kiffer,Carlos R.V.; Kuti,Joseph L.; Mendes,Caio M.F.; Oplustil,Carmen P.; Amarante,Jorge B.; Biancalana,Maria L.; Xavier,Nelson; Nicolau,David P.. Pharmacodynamic analyses were proposed to determine optimal empirical antibiotic therapy against Gram-negative bacteria isolated in a Brazilian ICU. Due to high resistance rates, standard regimens of cefepime, ciprofloxacin, meropenem, and piperacillin/tazobactam were not able to attain significant bactericidal CFR. Prolonged infusion of meropenem achieved 88% CFR, making it a possible empirical regimen in this ICU until susceptibilities become available. Still, even through administration of high dose prolonged infusions, 12.0% of simulated subjects did not achieve bactericidal exposure, suggesting that combination therapy would frequently be required in this setting. In conclusion, we recommend that in the presence of identified resistance problems among... Tipo: Info:eu-repo/semantics/article Palavras-chave: Pharmacodynamics; Resistance; Carbapenem; Meropenem. Ano: 2007 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702007000200001 Risk factors for pan-resistant Pseudomonas aeruginosa bacteremia and the adequacy of antibiotic therapy 55 Tuon,Felipe F.; Gortz,Lucas W.; Rocha,Jaime L.. INTRODUCTION: The aim of this study was to determine risk factors for acquiring carbapenemresistant Pseudomonas aeruginosa bacteremia (CR-PA) and factors associated with in-hospital mortality. METHODS: Seventy-seven cases of bacteremia caused by P. aeruginosa were evaluated in a hospital with high incidence of CR-PA. Clinical and laboratorial factors, and previous use of antibiotics were also evaluated. In one analysis, CR-PA and carbapenem-susceptible P. aeruginosa (CS-PA) bacteremia were compared. A second analysis compared patients who died with survivors. RESULTS: Among 77 P. aeruginosa bacteremia, 29 were caused by CR-PA. Admission to the intensive care unit, higher number of total leukocytes, and previous use of carbapenem were statistically... Tipo: Info:eu-repo/semantics/article Palavras-chave: Pseudomonas aeruginosa; Imipenem; Meropenem; Antibiotic resistance; Risk factor. Ano: 2012 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702012000400007 Treatment of nosocomial pneumonia: an experience with meropenem 55 Santos,Sigrid S.; Machado,Flavia R; Kiffer,Carlos R. V.; Barone,Antonio A.. This study aimed at evaluating the efficacy and safety of meropenem as first choice treatment for nosocomial pneumonia (NP) in intensive care units (ICU) in Hospital das Clínicas (HC) - University of São Paulo; a hospital with high incidence of antimicrobial resistance. Prospective, open, and non-comparative trial with meropenem were done in patients with ventilator-associated or aspiration NP in 2 ICUs at HC - University of São Paulo. Etiologic investigation was done through bronchoalveolar lavage and blood cultures prior to study entry. Twenty-five (25) critically ill patients with NP were enrolled (mean age 40 years). Ventilator-acquired pneumonia was responsible for 76% of cases and aspiration NP for 24%. Specific etiologic agents were identified and... Tipo: Info:eu-repo/semantics/article Palavras-chave: Meropenem; Nosocomial pneumonia; Intensive care unit. Ano: 2001 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702001000300004 Registros recuperados: 5 Primeira ... 1 ... Última

Empresa Brasileira de Pesquisa Agropecuária - Embrapa Todos os direitos reservados, conforme Lei n° 9.610 Política de Privacidade Área restrita		Embrapa Parque Estação Biológica - PqEB s/n° Brasília, DF - Brasil - CEP 70770-901 Fone: (61) 3448-4433 - Fax: (61) 3448-4890 / 3448-4891 SAC: https://www.embrapa.br/fale-conosco